Karyopharm’s Xpovio In Multiple Myeloma Priced At $22,000 Per Four-Week Cycle

 
• By Joseph Haas
  
FDA approved
Karyopharm's accelerated approval now awaits confirmatory Phase III data
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from New Products

More from Scrip